Recent studies have suggested that hypertension development may be associated with an altered immune system. However, there is a paucity of data evaluating the association between blood pressure values and inflammatory markers in patients with new-onset hypertension.

Material and methods:
We evaluated 61 subjects, including 24 healthy individuals and 37 newly diagnosed hypertensive patients (aged 45 ±9.6 vs. 43.8 ±11.9 years; SBP_24hours 114 ±7.1 vs. 134.2 ±9.5 mm Hg; DBP_24hours 71.2 ±4.7 vs. 85.8 ±9.3 mm Hg, respectively) without prior antihypertensive treatment. The diagnosis of hypertension was based on 24-hour ambulatory blood pressure monitoring (ABPM). We analysed the association between blood pressure values and levels of individual inflammatory markers (ITAC, GM-CSF, fractalkine, IFN-g, IL-10, MIP-3a, IL-12, IL-13, IL-17A, IL-1b, IL-2, IL-21, IL-23, IL-5, IL-6, IL-7, IL-8, MIP-1a, MIP-1b, TNF-a, and IL-15) separately, as well as in clusters of inflammatory mediators (factor 1 – proinflammatory: IL-1β, IL2, IL-6, IL-7, IL-12, IL-6, IL-21, TNF-α, IFN-γ; and factor 2 – anti-inflammatory: IL-13, IL-5).

Our study did not show any differences in concentrations of inflammatory markers between patients and controls. Plasma levels of inflammatory markers were not associated with 24-hour ambulatory blood pressure values in patients with new-onset hypertension.

Patients with new-onset hypertension did not differ from healthy subjects regarding the levels of plasma inflammatory markers. Our findings demonstrate the need for larger, more comprehensive studies on this topic to further elucidate the relationship between hypertension and inflammation.

Drummond GR, Vinh A, Guzik TJ, Sobey CG. Immune mechanisms of hypertension. Nat Rev Immunol 2019; 19: 517-32.
Rizzoni D, De Ciuceis C, Szczepaniak P, Paradis P, Schif frin EL, Guzik TJ. Immune system and microvascular re modeling in humans. Hypertension 2022; 79: 691-705.
Murray EC, Nosalski R, MacRitchie N, et al. Therapeutic targeting of inflammation in hypertension: from novel mechanisms to translational perspective. Cardiovasc Res 2021; 117: 2589-609.
Trott DW, Thabet SR, Kirabo A, et al. Oligoclonal CD8+ T cells play a critical role in the development of hyperten sion. Hypertension 2014; 64: 1108-15.
Guzik TJ, Hoch NE, Brown KA, et al. Role of the T cell in the genesis of angiotensin II induced hypertension and vascular dysfunction. J Exp Med 2007; 204: 2449-60.
Sundgren NC, Vongpatanasin W, Boggan BM, et al. IgG receptor FcgammaRIIB plays a key role in obesity-in duced hypertension. Hypertension 2015; 65: 456-62.
Madhur MS, Lob HE, McCann LA, et al. Interleukin 17 promotes angiotensin II-induced hypertension and vas cular dysfunction. Hypertension 2010; 55: 500-7.
Silva IVG, de Figueiredo RC, Rios DRA. Effect of different classes of antihypertensive drugs on endothelial func tion and inflammation. Int J Mol Sci 2019; 20: 3458.
Oparil S, Acelajado MC, Bakris GL, et al. Hypertension. Nat Rev Dis Primers 2018; 4: 18014.
Siedlinski M, Jozefczuk E, Xu X, et al. White blood cells and blood pressure: a Mendelian randomization study. Circulation 2020; 141: 1307-17.
Jayedi A, Rahimi K, Bautista LE, Nazarzadeh M, Zargar MS, Shab-Bidar S. Inflammation markers and risk of de veloping hypertension: a meta-analysis of cohort stud ies. Heart 2019; 105: 686-92.
De Miguel C, Rudemiller NP, Abais JM, Mattson DL. In flammation and hypertension: new understandings and potential therapeutic targets. Curr Hypertens Rep 2015; 17: 507.
Rothman AM, MacFadyen J, Thuren T, et al. Effects of interleukin-1beta inhibition on blood pressure, incident hypertension, and residual inflammatory risk: a second ary analysis of CANTOS. Hypertension 2020; 75: 477-82.
Timasheva YR, Nasibullin TR, Zakirova AN, Mustafina OE. Association of interleukin-6, interleukin-12, and interleukin-10 gene polymorphisms with essential hy pertension in Tatars from Russia. Biochem Genet 2008; 46: 64-74.
McMaster WG, Kirabo A, Madhur MS, Harrison DG. In flammation, immunity, and hypertensive end-organ damage. Circ Res 2015; 116: 1022-33.
O’Brien E, Mee F, Atkins N, O’Malley K. Accuracy of the SpaceLabs 90207 determined by the British Hyperten sion Society protocol. J Hypertens 1991; 9: 573-4.
Williams B, Mancia G, Spiering W, et al. 2018 Practice Guidelines for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension. Blood Press 2018; 27: 314-40.
Van Bortel LM, Laurent S, Boutouyrie P, et al.; Artery So ciety; European Society of Hypertension Working Group on Vascular Structure and Function; European Network for Noninvasive Investigation of Large Arteries. Expert consensus document on the measurement of aortic stiffness in daily practice using carotid-femoral pulse wave velocity. J Hypertens 2012; 30: 445-8.
Levey AS, Greene T, Kusek JW, Beck GJ. A simplified equation to predict GFR from serum creatinine. Am J Kidney Dis 2002; 39 (2 suppl.): S76-S110.
Vazquez-Oliva G, Fernandez-Real JM, Zamora A, Vilas eca M, Badimon L. Lowering of blood pressure leads to decreased circulating interleukin-6 in hypertensive sub jects. J Hum Hypertens 2005; 19: 457-62.
Charkiewicz AE, Garley M, Ratajczak-Wrona W, et al. The diagnostic potential of novel biomarkers of hyper tension in men. Arch Med Sci 2022; 18: 1666-71.
Stumpf C, John S, Jukic J, et al. Enhanced levels of platelet P-selectin and circulating cytokines in young patients with mild arterial hypertension. J Hypertens 2005; 23: 995-1000.
Yao W, Sun Y, Wang X, Niu K. Elevated serum level of interleukin 17 in a population with prehypertension. J Clin Hypertens (Greenwich) 2015; 17: 770-4.
Amador CA, Barrientos V, Pena J, et al. Spironolactone decreases DOCA-salt-induced organ damage by block ing the activation of T helper 17 and the downregula tion of regulatory T lymphocytes. Hypertension 2014; 63: 797-803.
Awad K, Zaki MM, Mohammed M, et al. Effect of the renin-angiotensin system inhibitors on inflammato ry markers: a systematic review and meta-analysis of randomized controlled trials. Mayo Clin Proc 2022; 97: 1808-23.
Ugovsek S, Zupan J, Likozar AR, Sebestjen M. Influence of lipid-lowering drugs on inflammation: what is yet to be done? Arch Med Sci 2022; 18: 855-69.
Crouch SH, Botha-Le Roux S, Delles C, Graham LA, Schutte AE. Inflammation and hypertension develop ment: a longitudinal analysis of the African-PREDICT study. Int J Cardiol Hypertens 2020; 7: 100067.
Harrison DG, Vink A, Lob H, Madhur MS. Role of the adaptive immune system in hypertension. Curr Opin Pharmacol 2010; 10: 203-7.
Rysz J, Banach M, Cialkowska-Rysz A, et al. Blood serum levels of IL-2, IL-6, IL-8, TNF-alpha and IL-1beta in pa tients on maintenance hemodialysis. Cell Mol Immunol 2006; 3: 151-4.
Dobrowolski P, Prejbisz A, Kurylowicz A, et al. Metabolic syndrome – a new definition and management guide lines: A joint position paper by the Polish Society of Hy pertension, Polish Society for the Treatment of Obesity, Polish Lipid Association, Polish Association for Study of Liver, Polish Society of Family Medicine, Polish So ciety of Lifestyle Medicine, Division of Prevention and Epidemiology Polish Cardiac Society, “Club 30” Polish Cardiac Society, and Division of Metabolic and Bariatric Surgery Society of Polish Surgeons. Arch Med Sci 2022; 18: 1133-56.
Surma S, Sahebkar A, Banach M. Coffee or tea: Anti-in flammatory properties in the context of atherosclerot ic cardiovascular disease prevention. Pharmacol Res 2023; 187: 106596.
Chrusciel P, Stemplewska P, Stemplewski A, et al. Asso ciations between the lipid profile and the development of hypertension in young individuals – the preliminary study. Arch Med Sci 2022; 18: 25-35.
Ryczkowska K, Adach W, Janikowski K, Banach M, Bielecka-Dabrowa A. Menopause and women’s cardio vascular health: Is it really an obvious relationship? Arch Med Sci 2023; 19: 458-66.
Journals System - logo
Scroll to top